Advertisement

Document › Details
ITM Isotope Technologies Munich SE. (2/1/24). "Press Release: ITM Obtains Manufacturing License in the U.S.". Garching & Princeton, NJ.
![]() |
Organisation | ITM Isotope Technologies Munich SE |
Today | Isotopen Technologien München AG | |
Group | ITM (Group) | |
Organisation 2 | ITM Isotope Technologies Munich US Headquarters in Princeton, NJ | |
Group | ITM (Group) | |
![]() |
Product | RADIOPHARMACEUTICAL (RPT) |
Product 2 | lutetium-177 (medical isotope) | |
![]() |
Person | Schuster, Steffen (ITM Isotopen Technologien München 201603 CEO) |
Person 2 | Orzelek, Ben (ITM 202111– Head of Investor Relations befoore Sartorius) | |
License will support ITM’s efforts in preparing for the commercialization of its diagnostic and therapeutic radiopharmaceutical pipeline across the U.S.
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the company has obtained a wholesale license issued by the New Jersey Department of Health (NJDOH) in order to operate as a virtual manufacturer. Obtaining the wholesale license is a pivotal requirement for ITM’s business activities in the United States. This milestone enables the company to distribute its radiopharmaceutical products, thereby facilitating patient access to ITM’s radiopharmaceuticals upon their approval by the U.S. Food and Drug Administration (FDA).
ITM opened its U.S. headquarters in Princeton, New Jersey in April 2023. Upon opening its new offices, the company prepared for potential market registration of its targeted radiopharmaceutical pipeline product candidates and filed for obtaining the wholesale license. After an inspection from regulatory bodies that found no deficiencies, the wholesale license was issued to ITM on January 16, 2024.
“Obtaining the wholesale license is a crucial step in expanding our U.S. business as we prepare for the future launch of both our diagnostic and therapeutic radiopharmaceutical products in this important geography,” commented Steffen Schuster, CEO of ITM. “With this license and our U.S. team in place, we are on the right path to growing our capabilities in serving the healthcare community, our partners, and most importantly, patients on a global scale.”
About Radiopharmaceutical Therapy (RPT)
Radiopharmaceutical Therapy (RPT) is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to normal tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope such as Lutetium-177 or Actinium-225 to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, such as receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, with the goal of destroying tumor tissue. The precise localization enables targeted treatment with potentially minimal impact to healthy surrounding tissue.
About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com
ITM Contact
Corporate Communications
Gerrit Siegers
Phone: +49 89 329 8986 1502
Email: [email protected]
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: [email protected]
Record changed: 2024-11-04 |
Advertisement

More documents for ITM (Group)
- [1] ITM Isotope Technologies Munich SE. (12/13/24). "Press Release: ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference". Garching / Munich....
- [2] ITM Isotope Technologies Munich SE. (6/20/24). "Press Release: ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth". Garching....
- [3] ITM Isotope Technologies Munich SE. (6/6/24). "Press Release: ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing". Garching....
- [4] ITM Isotope Technologies Munich SE. (1/30/24). "Press Release: ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program". Garching & Vancouver, BC....
- [5] ITM Isotope Technologies Munich SE. (1/16/24). "Press Release: ITM Appoints Dr. Mark Harfensteller as Member of Its Executive Board". Garching....
- [6] ITM Isotope Technologies Munich SE. (1/4/24). "Press Release: ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site". Garching....
- [7] ITM Isotope Technologies Munich SE. (12/21/23). "Press Release: ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference". Garching....
- [8] ITM Isotope Technologies Munich SE. (12/14/23). "Press Release: ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics". Garching....
- [9] ITM Isotope Technologies Munich SE. (7/31/23). "Press Release: ITM and Point Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177". Garching & Indianapolis, IN....
- [10] ITM Isotope Technologies Munich SE. (6/13/23). "Press Release: ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer". Neufahrn, Garching & Munich....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top